Skip to main content
Smart Investors Daily
Beyond Air, Inc. logo

NASDAQ · XAIR

Beyond Air, Inc.

Healthcare · Medical - Devices

$2.21

Down-$0.03 (-1.34%)

Updated Nov 3, 2026, 9:44 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.6M
P/E ratio
-0.13
Dividend yield
0.00%
52-week range
$0.33 – $9.28
Volume
36.45K
Avg. volume
537.56K

Price performance · XAIR

XAIR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

XAIR closed at $2.21 after 21 trading sessions, down 22.18% for the selected period.

Last close
$2.21
Period change
-22.18%
Period low
$2.09
Period high
$2.84
Daily close
View OHLC price history
XAIR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$2.325$2.485$2.1705$2.2136.45K
Oct 30, 2026$2.28$2.39$2.24$2.2412.52K
Oct 29, 2026$2.36$2.43$2.30$2.3116.53K
Oct 28, 2026$2.235$2.36$2.1601$2.3621.14K
Oct 27, 2026$2.17$2.29$2.17$2.2110.46K
Oct 26, 2026$2.1222$2.24$2.1222$2.1413.17K
Oct 23, 2026$2.28$2.28$2.05$2.0920.82K
Oct 22, 2026$2.27$2.2992$2.195$2.299212.32K
Oct 21, 2026$2.27$2.34$2.16$2.3428.89K
Oct 20, 2026$2.15$2.29$2.15$2.1917.71K
Oct 19, 2026$2.22$2.22$2.12$2.1356.82K
Oct 16, 2026$2.22$2.2699$2.122$2.1614.69K
Oct 15, 2026$2.14$2.24$2.07$2.2133.18K
Oct 14, 2026$2.18$2.25$2.05$2.1059.09K
Oct 13, 2026$2.35$2.37$2.16$2.1936.37K
Oct 12, 2026$2.27$2.47$2.24$2.3130.21K
Oct 9, 2026$2.30$2.335$2.20$2.2565.39K
Oct 8, 2026$2.76$2.76$2.31$2.31100.04K
Oct 7, 2026$2.49$2.60$2.47$2.5436.21K
Oct 6, 2026$2.76$2.82$2.545$2.5536.48K
Oct 5, 2026$2.93$2.99$2.806$2.8443.09K

Latest XAIR news

The latest Smart Investors Daily articles mentioning XAIR.

XAIR research

Overview

Company profile and research snapshot.

Company profile

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$1.00
Implied upside
—
Analysts
11
XAIR recent ratings
DateFirmRatingTarget
Sep 1, 2026Lake StreetBuy—
Mar 27, 2026D. Boral CapitalBuy—
Mar 18, 2026D. Boral CapitalBuy—
Mar 10, 2026D. Boral CapitalBuy—
Jan 21, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026

GARDEN CITY, N.Y., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its quarter ended September 30, 2026 on Wednesday, November 11, 2026. The Company's management team is scheduled to host a conference call and webcast at 4:30 p.m. Eastern Time (E

Yahoo · Oct 8, 2026

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance reflects continued adoption for first-generation LungFit PH; second-generation system remains under FDA review Reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 GARDEN CITY, N.Y., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Comp

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.